Citius Oncology (CTOR) Share-based Compensation (2023 - 2026)
Citius Oncology (CTOR) posted quarterly Share-based Compensation of $3.7 million for Q1 2026, up 77.36% year-over-year from $2.1 million in Q1 2025, and down 6.37% quarter-over-quarter from $4.0 million in Q4 2025.
Citius Oncology (CTOR) Share-based Compensation (2023 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Share-based Compensation for 4 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 77.36% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $3.7 million (down 72.77% YoY), while the FY2025 annual figure was $8.3 million, down 28.23% from the prior year.
- Share-based Compensation retreated to $3.7 million in Q1 2026 per CTOR's latest filing, from $4.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $11.6 million in Q3 2024 and bottomed at $1.8 million in Q4 2024.
- Historically, Share-based Compensation has averaged $3.9 million across 4 years, with a median of $3.0 million in 2025.
- On a YoY basis, Share-based Compensation climbed as much as 118.75% in 2025 and fell as far as 80.18% in 2025.
- Citius Oncology's Share-based Compensation stood at $1.9 million in 2023, then fell by 5.66% to $1.8 million in 2024, then jumped by 118.75% to $4.0 million in 2025, then fell by 6.37% to $3.7 million in 2026.
- Business Quant data shows CTOR's Share-based Compensation at $3.7 million in Q1 2026, $4.0 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Citius Oncology | 80.25 Mn | 80.25 Mn | 1.00 Mn | 3.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.70 Mn |
| Mar 31, 2026 | 3.70 Mn |
| Dec 31, 2025 | 3.96 Mn |
| Dec 31, 2025 | 3.96 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Mar 31, 2025 | 2.09 Mn |
| Mar 31, 2025 | 2.09 Mn |
| Dec 31, 2024 | 1.81 Mn |
| Dec 31, 2024 | 1.81 Mn |
| Sep 30, 2024 | 11.59 Mn |
| Sep 30, 2024 | 11.59 Mn |
| Jun 30, 2024 | 5.83 Mn |
| Jun 30, 2024 | 5.83 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Dec 31, 2023 | 1.92 Mn |
| Dec 31, 2023 | 1.92 Mn |